The appointment of a new CMO with extensive experience in neuroscience and rare diseases is likely to positively impact Rapport Therapeutics' clinical strategy and development of precision medicines. This strategic leadership change could enhance investor confidence and potentially lead to advancements in their CNS disorder treatments.